



Attorney Docket No.: 6531.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Skyggebjerg et al.

Serial No.: 10/618,878

Group Art Unit: To Be Assigned

Filed: July 14, 2003

Examiner: To Be Assigned

For: Device With Time Indicating Means

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

I hereby certify that the attached correspondence comprising:

1. Information Disclosure Statement
2. Form PTO-1449
3. Copy of References

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on October 10, 2003

Rashida Haji
(name of person mailing paper)

Rashida Haji
(signature of person mailing paper)



Attorney Docket No.: 6531.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Skyggebjerg et al.

Application No.: 10/618,878

Group Art Unit: To Be Assigned

Filed: July 14, 2003

Examiner: To Be Assigned

For: Device With Time Indicating Means

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:


In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no material references other than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is also enclosed. The references are as follows:

1. US Patent No.5,598,567
2. US Patent No. 6,248,090 B1
3. EP 0 087 491
4. FR 2 820 311
5. DE 3824217 A1

FORM PTO-1449
(Rev. 2-32)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

Atty. Docket No. 6531.200-US

Serial No. 10/618,878

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant Skyggebjerg et al.

Filing Date July 14, 2003

Group To Be Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5,598,567	1-28-97	Ninomiya	395	750	
	6,248,090 B1	6-19-01	Jensen et al.	604	67	

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	0 087 491	9-7-83	EP				x
	2 820 311	1-23-02	FR				x
	3824217 A1	1-18-90	DE				x

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the undersigned if there are any questions concerning this paper or the attached references.

The information disclosure statement submitted herewith is being filed **within** three months of the filing date of a national application or date of entry into the national stage of an international application or **before** the mailing date of a first Office action on the merits, or **before** the mailing date of a first Office action after the filing of a request for continued examination. Therefore, no fee is due. However, please charge any fees should they be required, to Novo Nordisk Pharmaceuticals, Inc. Deposit Account No. 14-1447.

Respectfully submitted,

Date: October 10, 2003



Marc A. Began, Reg. No. 48,829
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5800

23650
PATENT TRADEMARK OFFICE